Mario Gabelli Inozyme Pharma, Inc. Transaction History
Gamco Investors, Inc. Et Al
- $9.45 Billion
- Q3 2025
Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
4Shares Held
4.86MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY1.27MShares$5.08 Million2.63% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL250KShares$1 Million0.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$0100.0% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...